ADCIRCA is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by United Therapeutics Corporation. The primary component is Tadalafil.
Product ID | 66302-467_030624e0-c32a-4d87-9380-4fea81d63799 |
NDC | 66302-467 |
Product Type | Human Prescription Drug |
Proprietary Name | ADCIRCA |
Generic Name | Tadalafil |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2009-05-22 |
Marketing Category | NDA / NDA |
Application Number | NDA022332 |
Labeler Name | United Therapeutics Corporation |
Substance Name | TADALAFIL |
Active Ingredient Strength | 20 mg/1 |
Pharm Classes | Phosphodiesterase 5 Inhibitor [EPC],Phosphodiesterase 5 Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2009-08-03 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA022332 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2011-05-11 |
Marketing Category | NDA |
Application Number | NDA022332 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | EA |
Marketing Start Date | 2009-08-03 |
Ingredient | Strength |
---|---|
TADALAFIL | 20 mg/1 |
SPL SET ID: | ff61b237-be8e-461b-8114-78c52a8ad0ae |
Manufacturer | |
UNII | |
RxNorm Concept Unique ID - RxCUI | |
UPC Code |
NDC | Brand Name | Generic Name |
---|---|---|
43353-070 | ADCIRCA | ADCIRCA |
66302-467 | ADCIRCA | ADCIRCA |
0093-3334 | ALYQ | Tadalafil |
0002-4462 | Cialis | Tadalafil |
0002-4463 | Cialis | Tadalafil |
0002-4464 | Cialis | Tadalafil |
0002-4465 | Cialis | Tadalafil |
0093-3016 | Tadalafil | Tadalafil |
0093-3017 | Tadalafil | Tadalafil |
0093-3018 | Tadalafil | Tadalafil |
0093-3019 | Tadalafil | Tadalafil |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
ADCIRCA 78737811 not registered Dead/Abandoned |
ELI LILLY AND COMPANY 2005-10-21 |
ADCIRCA 77860178 3844162 Live/Registered |
Eli Lilly and Company 2009-10-29 |
ADCIRCA 77262532 3677077 Live/Registered |
Eli Lilly and Company 2007-08-23 |